olaparib,177lu-psma-617
novartis,astrazeneca,merck
['crpc', 'prostate', '177lu,psma,617', 'olaparib', 'psma-617 ']
looking forward to #asco23 presentation by - #luparp: phase 1 trial of 177lu-psma-617 and #olaparib in patients w/ metastatic castration-resistant #prostatecancer #mcrpc. don't miss written coverage following on urotoday! 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology